GSA Capital Partners’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

GSA Capital Partners’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-36,587	Closed	-$98K	–	2031
2023 Q3	$98K	Buy	+36,587	New	+$143K	0.01%	1389
2023 Q2	–	Sell	-17,543	Closed	-$156K	–	2045
2023 Q1	$156K	Buy	+17,543	New	+$172K	0.02%	1302

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

GSA Capital Partners's THRX Position: Q4 2023 in Review

GSA Capital Partners sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2023, closing a stake of 36,587 shares — an estimated $98K sold.

GSA Capital Partners first reported a position in THRX in Q1 2023 and held it in 2 quarters. The position peaked at $156K in Q1 2023. 70 funds tracked by Wall St. Rank hold THRX as of Q4 2023.

GSA Capital Partners reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
GSA Capital Partners sold 36,587 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $98K.
GSA Capital Partners first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
GSA Capital Partners's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $156K in Q1 2023.
70 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.